sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Reports EGM Results
GenSight Biologics, a biopharmaceutical company based in Paris, announced the outcomes of its Extraordinary General Meeting held on January 28, 2026. All proposed resolutions were approved except the 8th, which concerned a reserved capital increase and was rejected by shareholders.
The approval of key financial authorizations ensures that the company retains the financial flexibility essential for pursuing its strategy. Deputy CEO and CFO, Jan Eryk Umiastowski, chaired the meeting, addressing questions from shareholders and providing clarifications as needed.
The rejection of the 8th resolution does not impact the company's capacity to handle future capital transactions. Detailed results of the vote and a meeting replay are available on GenSight’s website.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.